GlassScriptPhysician profile
Leith A Abdulla
NPI 1861606782
$1,964.51
in general payments reported to CMS, 2019-2025
26 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.56 · 2020: $96.24 · 2021: $200 · 2022: $236 · 2023: $303 · 2024: $361 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $308.19 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $220.16 | 2022-2025 | |
| Pfizer INC. | $111.10 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.82 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $106.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.87 | 2022-2025 | Lifevest |
| Exact Sciences Corporation | $105.65 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $101.92 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $95.70 | 2022-2025 | |
| Shield Therapeutics INC | $81.28 | 2023-2024 | Accrufer |
| Actelion Pharmaceuticals US, INC. | $78.40 | 2025 | Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $72.19 | 2022-2025 | Verquvo |
| Amarin Pharma, INC. | $66.53 | 2020-2021 | |
| Lilly USA, LLC | $59.34 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $50.03 | 2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $45.84 | 2024-2025 | Ecc Solutions, (Ck7) Extended Holter |
| Janssen Pharmaceuticals, INC | $33.56 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.97 | 2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $30.67 | 2025 | |
| United Therapeutics Corporation | $28.86 | 2025 | Tyvaso |
| Ars Pharmaceuticals Operations, INC. | $24.07 | 2025 | Neffy |
| Boston Scientific Corporation | $23.46 | 2023 | Bodyguardian |
| Medicomp INC | $21.91 | 2024 | Telepatch Cardiac Monitor |
| Heartflow, INC. | $18.91 | 2025 | |
| Abbvie INC. | $15.63 | 2021 | |
| Irhythm Technologies, INC. | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leith Abdulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.